Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

High Ki67 expression is a risk marker of invasive relapse for classical lobular carcinoma in situ patients.

Vincent-Salomon A, Hajage D, Rouquette A, C├ędenot A, Gruel N, Alran S, Sastre-Garau X, Sigal-Zafrani B, Fourquet A, Kirova Y.

Breast. 2012 Jun;21(3):380-3. doi: 10.1016/j.breast.2012.03.005. Epub 2012 Apr 22.

PMID:
22531230
2.

Is there a low-grade precursor pathway in breast cancer?

King TA, Sakr RA, Muhsen S, Andrade VP, Giri D, Van Zee KJ, Morrow M.

Ann Surg Oncol. 2012 Apr;19(4):1115-21. doi: 10.1245/s10434-011-2053-0. Epub 2011 Sep 21.

PMID:
21935747
3.
4.

Expression of ERalpha and ERbeta in lobular carcinoma in situ.

Middleton LP, Perkins GH, Tucker SL, Sahin AA, Singletary SE.

Histopathology. 2007 Jun;50(7):875-80.

PMID:
17543077
5.

Lobular carcinoma in situ increases the risk of local recurrence in selected patients with stages I and II breast carcinoma treated with conservative surgery and radiation.

Sasson AR, Fowble B, Hanlon AL, Torosian MH, Freedman G, Boraas M, Sigurdson ER, Hoffman JP, Eisenberg BL, Patchefsky A.

Cancer. 2001 May 15;91(10):1862-9.

PMID:
11346867
6.
7.
8.
9.

Multicentric mammary carcinoma: evidence of monoclonal proliferation.

Middleton LP, Vlastos G, Mirza NQ, Eva S, Sahin AA.

Cancer. 2002 Apr 1;94(7):1910-6.

10.

The expression of ERalpha, ERbeta and PR in lobular carcinoma in situ of the breast determined using laser microdissection and real-time PCR.

Green AR, Young P, Krivinskas S, Rakha EA, Claire Paish E, Powe DG, Ellis IO.

Histopathology. 2009 Mar;54(4):419-27. doi: 10.1111/j.1365-2559.2009.03233.x.

PMID:
19309393
11.

Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Five-year observations concerning lobular carcinoma in situ.

Fisher ER, Costantino J, Fisher B, Palekar AS, Paik SM, Suarez CM, Wolmark N.

Cancer. 1996 Oct 1;78(7):1403-16.

12.

Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.

Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P.

Breast J. 2005 Jul-Aug;11(4):278-80.

PMID:
15982396
13.
16.

Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse.

Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, Banham AH.

J Clin Oncol. 2006 Dec 1;24(34):5373-80.

PMID:
17135638
17.

Disparate E-cadherin mutations in LCIS and associated invasive breast carcinomas.

Rieger-Christ KM, Pezza JA, Dugan JM, Braasch JW, Hughes KS, Summerhayes IC.

Mol Pathol. 2001 Apr;54(2):91-7.

18.

Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity.

Reis-Filho JS, Simpson PT, Jones C, Steele D, Mackay A, Iravani M, Fenwick K, Valgeirsson H, Lambros M, Ashworth A, Palacios J, Schmitt F, Lakhani SR.

J Pathol. 2005 Sep;207(1):1-13.

PMID:
15957152
19.

P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancer.

Turashvili G, McKinney SE, Goktepe O, Leung SC, Huntsman DG, Gelmon KA, Los G, Rejto PA, Aparicio SA.

Mod Pathol. 2011 Jan;24(1):64-81. doi: 10.1038/modpathol.2010.189. Epub 2010 Sep 17.

20.

Supplemental Content

Support Center